logo

Clinical Trial Results

Share

pharmaup-april24.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharma-031717_23apr19.jpg The following are some of today's top gainers in the pharma/biotech sector.

Teva Pharmaceutical Industries Ltd. (TEVA) said it is discontinuing the clinical development program for use of fremanezumab in cluster headaches as a pre-specified futility analysis of a Phase III study showed that the primary endpoint is unlikely to be met. Also, Teva is stopping the ENFORCE Phase...

Eli Lilly and Company (LLY) reported top-line results from a phase 3 study on Taltz for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in patients who are biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve. Taltz met the primary and all secondary endpoints, at both week...

bubbleboy-april18.jpg Shares of Mustang Bio Inc. (MBIO) soared more than 349 percent to $11.96 in extended trading on Wednesday, following encouraging results of the company's MB-107, an investigational lentiviral gene therapy for the treatment of bubble boy disease.

pharmaup-april16.jpg The following are some of today's top gainers in the pharma/biotech sector.

q2-april16.jpg Shares of Axsome Therapeutics Inc. (AXSM) rose more than 6% on Monday, following positive results from its phase II trial of AXS-05 for smoking cessation treatment. Let's take a look at some more biotech companies awaiting phase II or phase III clinical trial results this quarter.

TRACON Pharmaceuticals, Inc. (TCON) announced Friday that its Phase 3 TAPPAS trial was terminated for futility based on the recommendation of the Independent Data Monitoring Committee (IDMC). The trial was evaluating TRC105 in combination with Votrient (pazopanib) in patients with advanced or metastatic...

pharmadown-april10.jpg The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

pharmaup-april10.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharmaup-april09.jpg The following are some of today's top gainers in the pharma/biotech sector.

Alkermes plc (ALKS) announced Tuesday positive topline results from ALPINE (Aripiprazole Lauroxil and Paliperidone palmitate: INitiation Effectiveness), a first-of-its-kind, six-month study evaluating the efficacy, safety and tolerability of ARISTADA (aripiprazole lauroxil) and INVEGA SUSTENNA (paliperidone...

pharmaup-april08.jpg The following are some of today's top gainers in the pharma/biotech sector.

United Therapeutics Corp. (UTHR) announced Monday that the BEAT clinical study of esuberaprost tablets in patients suffering from pulmonary arterial hypertension did not meet its primary endpoint of delayed time to first clinical worsening event. Accordingly, United Therapeutics has decided to discontinue...

pharmadown-april02.jpg The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

Follow RTT